UBS Group
KLRA

UBS Group’s Kailera Therapeutics KLRA Stock Holding History

UBS Group’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
+972,683
New +$21.4M ﹤0.01% 2609

Other funds holding KLRA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's KLRA Position: Q2 2026 in Review

UBS Group opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 972,683 shares worth $21.4M. The stake represents ﹤0.01% of the portfolio and ranks #2609 among its holdings.

47 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • UBS Group held 972,683 shares of Kailera Therapeutics worth $21.4M as of Q2 2026.
  • Kailera Therapeutics was a new UBS Group position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2609 holding.
  • 47 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.